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Dynamic contrast-enhanced MR imaging (DCE-MRI) may act as a biomarker for successful cancer therapy. Simple, reproducible
techniques may widen this application. This paper demonstrates a single slice imaging technique. The image acquisition is performed
in less than 500ms making it relatively insensitive to respiratory motion. Data from phantom studies and a reproducibility study in
solid human tumours are presented. The reproducibility study showed a coefficient of variation (CoV) of 19.1% for K
trans and 15.8%
for the initial area under the contrast enhancement curve (IAUC). This was improved to 16 and 13.9% if tumours of diameter less
than 3cm were excluded. The individual repeatability (the range within which individual measurements are expected to fall) was
30.6% for K
trans and 26.5% for IAUC for tumours greater than 3cm diameter. This approach to DCE–MRI image acquisition can be
performed with standard clinical scanners, and data analysis is straightforward. For treatment trials with 10 patients in a cohort, the
CoV implies that the method would be sensitive to a treatment effect of greater than 18%. The individual repeatability is well inside
the 40% change shown to be important in clinical studies using this DCE–MRI technique.
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Dynamic contrast-enhanced magnetic resonance imaging (DCE–
MRI) is the continuous acquisition of MR images over a period of
between 1 and 20min after the injection of a contrast agent into a
peripheral vein, typically in the antecubital fossa. Normally, this
involves a gadolinium chelate, which causes an increase in signal
intensity on T1-weighted MR images. The increase in signal
intensity (enhancement) is caused by the change in the nuclear
spin relaxation rate R1 (R1¼1/T1), which is proportional to the
concentration of the contrast agent. Enhancement, as measured by
DCE–MRI, may be used to study the pathophysiology of tumours
(Taylor et al, 1999; Yuh, 1999; Morgan et al, 2004). Parameters of
interest include tumour vascularity, vascular endothelial perme-
ability and the volume fraction of the extravascular, extracellular
space (Knopp et al, 1999). There is an increasing interest in the use
of these techniques as biomarkers in the development of novel
cancer therapies (Jayson et al, 2002; Galbraith et al, 2003; Morgan
et al, 2003; Leach et al, 2005; Rehman and Jayson, 2005; Thomas
et al, 2005). Different approaches to the acquisition and analysis of
DCE–MRI studies have been reviewed elsewhere (Morgan et al,
2004; Buckley and Parker, 2005; Parker and Buckley, 2005).
Ideally, DCE–MRI data acquisition should have high spatial
resolution allowing mapping of enhancement parameters for the
tumour in a pixel-by-pixel manner. This is important for gaining
prognostic information about a tumour where small areas of
increased tumour activity could otherwise be missed (Degani et al,
1997; Parker et al, 1997). This approach typically involves image
acquisition times of between 6 and 30s for each image in the
dynamic series. As a large percentage of metastatic disease treated
by chemotherapy is in parts of the body that cannot be easily
immobilised, such as the liver and lung, pixel-by-pixel data
analysis is complicated by the need for sophisticated registration
of the tumour in consecutive images. Long imaging times also
involve multiple breath holds, which may be difficult for a patient
with advanced cancer. This suggests an approach with short image
acquisition times that can freeze motion and an analysis based on
the whole tumour as the region of interest. A rapid imaging
approach may also allow better depiction of the early part of the
contrast enhancement curve. Successful systemic treatment may be
expected to have an effect detectable by averaging the signal from
the whole region of interest (ROI), but changes that are restricted
to a small part of the tumour, or to poorly enhancing pixels, could
be missed.
One problem when analysing tumour microcirculation is that
signal intensities obtained from the MRI scanner are arbitrary and
need to be ‘standardised’ if comparisons between different patients
or patient visits are required. One possible method is by dividing
the signal change due to gadolinium enhancement by the
precontrast signal of the tumour (Mayr et al, 1999; Reddick
et al, 1999). This has the disadvantage that the precontrast R1 can
change during therapy, for example with increasing tumour
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soedema, causing an apparent change in enhancement (Evelhoch,
1999). A mechanism to standardise signal intensities is therefore
required that is not sensitive to changes in pre-contrast R1.
We have shown that high temporal resolution DCE–MRI, using
a single slice approach with a single ROI evaluating the whole
tumour cross-section, performed without breath holding, is
feasible and can act as a biomarker for the beneficial effects of
an anti-angiogenesis agent (Morgan et al, 2003; Thomas et al,
2005). However, in order to plan such trials it is important to know
the inherent variability of the results from the DCE–MRI approach
in order to assess the significance of individual changes, and to use
power statistics to determine the cohort sizes required to give
statistical significance for a desired effect.
When planning a multicentre clinical trial for patients with
advanced cancer, a DCE–MRI technique that is quick, does not
involve multiple breath holds and is applicable in all areas of the
body has obvious advantages. A validated, straightforward way of
analysing the data from DCE–MRI would allow wider application
of the technique. This study shows the rationale for developing a
single slice DCE–MRI technique and investigates different
approaches to standardising the measured signal intensities, and
analysing the time course of signal intensities from an ROI that
covers the whole tumour cross-section. The chosen imaging
sequence was performed in cancer patients on two occasions 1
week apart, without treatment, in order to assess the reproduci-
bility of several common approaches used for analysing DCE–MRI
data.
The results of this reproducibility analysis were then put in a
clinical context by re-analysing and comparing the data obtained
in a previous published clinical trial that successfully used this
technique as a biomarker (Thomas et al, 2005). In this dose
escalating phase I study, the pharmacodynamic effect of PTK787/
ZK222584 (PTK/ZK), an orally active inhibitor of vascular
endothelial growth factor (VEGF) receptor tyrosine kinases, which
inhibits VEGF-mediated angiogenesis, was evaluated.
MATERIALS AND METHODS
Pulse sequence
To achieve high temporal resolution and avoid the need for breath
holding, we used scan parameters with individual image acquisi-
tion times of less than 500ms, effectively freezing motion owing to
respiration. To achieve this, a repetition time (TR) of 5ms or less is
necessary for 100 phase encoding steps. T1 weighting can then be
created by applying a magnetisation preparation pulse (Snapshot
FLASH) (Haase, 1990). We used an inversion pulse for magnetisa-
tion preparation; this pulse was nonslice selective (i.e. affecting the
whole bore of the magnet) to minimise the effects of through-plane
motion and blood inflow. As respiratory motion in the abdomen
and lower part of the lung is largely in the cranio–caudal direction,
a coronal or sagittal oblique plane was used to keep the tumour
within the imaged slice during the dynamic run. The parameters of
the sequence used were: TR¼3.3ms, echo time (TE)¼1.4ms, flip
angle (a)¼81, k space matrix 100 phase encoding steps  128
points in the readout direction, inversion time (TI)¼655ms, and
time between successive inversion pulses (TR0)¼3000ms.
Quantification of R1
Assuming minimal transverse relaxation between the excitation
pulses and signal acquisition, the contrast obtained from an
inversion recovery snapshot FLASH sequence is affected by TR, TI,
a, the number of lines of k space (Nk) and the delay between the
end of image acquisition and the next inversion pulse (TD). From
previous work (Jivan et al, 1997), the z magnetisation after m
phase encoding steps relative to the equilibrium magnetisation
(M0) is given by:
Mz
M0
¼Cðm 1Þ 1 EI 1þ
1ED 1 CNkð1 EIÞ
  
þ
EDðER 1Þ CNk 1 ðÞ
C 1
  
1 þ ED CNk EI
8
> > <
> > :
9
> > =
> > ;
8
> > <
> > :
9
> > =
> > ;
þð 1   ERÞ
Cðm 1Þ   1
C   1
  
ð1Þ
where ER ¼e TR=T1 ,E I¼e TI=T1 ,E D¼e TD=T1 and C¼ERcosa.
The sum of TI, TD and (TR Nk)i sT R 0, the time between
successive inversion pulses. As TR0-N and a-0, then equation
(1) simplifies to
Mz
M0
¼ 1   2e TIeff=T1 ð2Þ
where TIeff is the time from the inversion pulse to the centre of k
space. The signal intensity is given by S¼Mzsina.
In order to provide data that are comparable between patient
visits, it is necessary to convert signal intensities to quantitative
data. One method is to calculate the relaxation rate R1, which can
be done by acquiring an image without the inversion pulse applied,
after the contrast enhanced run, removing a major component of
T1 weighting. The ratio of signal intensities with (S) and without
(S0) the inversion pulse is then related to the R1 of the tissue by
equations (1) and (2), from which R1 may be determined.
Phantom study
This approach to R1 estimation was tested in a phantom study. The
phantom consisted of vials of water doped with different
concentrations of Gd-DTPA giving a range of R1 values from 0.4
to 10s
 1. The R1 values were accurately measured using an IR-
prepared turbo spin echo (TSE) sequence with TE¼10ms,
TR¼5000ms, echo train length¼5, 128 128 matrix, 1.56mm
in plane resolution, 5mm slice thickness and inversion times of 23,
123, 323, 723 and 1520ms. Phantom work was carried out using a
Siemens symphony 1.5T system (Siemens, Erlangen, Germany).
Based on equation (1) this sequence effectively nulls signal at an R1
of 0.53s
 1. Where R1 was less than 0.53s
 1, the positive signal of
the magnitude images was inverted. In a DCE–MRI study, rectified
signal can be recognised if the signal reduces in the first few
images of contrast enhancement. The estimated R1 values, using
the chosen DCE–MRI sequence and equations. (1) and (2), were
compared with the accurately measured R1 values.
Clinical study
Eleven patients with advanced cancers, including colorectal
cancers with liver metastases, were recruited as part of two ‘phase
I’ trials. Patients had two DCE–MRI scans 1 week apart, without
treatment. All patients were informed about the investigational
nature of the study according to institutional and regional
guidelines, and subsequently gave informed consent before start
of the study. Permission of local ethics regulatory bodies was
obtained.
All MR images were acquired using a 1.5T whole body magnet
equipped with 25mTm
 1 gradient coils and phased array surface
coils (Siemens Magnetom Vision, Erlangen, Germany). All patients
underwent standard transverse breath hold gradient recalled echo
(GRE) T1 and TSE T2-weighted imaging of the tumour region
(GRE, typically TR¼150ms, TE¼4ms, a¼701 and matrix
256 256; TSE typically TR¼5000ms, TE¼90, a¼901, echo
train length¼23). In regions where respiratory motion was a
factor, the T1-weighted multislice GRE examination was repeated
during gentle respiration to improve slice positioning for the
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sdynamic series, which was also performed during gentle respira-
tion. A representative disease site was selected (target lesion) and a
single coronal oblique slice was planned to bisect the midline of
the tumour and a major blood vessel (usually aorta). This became
the imaged tumour for all subsequent scans. The DCE–MRI
sequence was then run with 100 measurements, 3s apart
(TR0¼3000ms). Low molecular weight gadolinium-chelate
0.1mmolkg
 1 (Magnevist, Schering AG or Omniscan, Nycomed)
was injected as a rapid bolus through an arm vein in less than 5s
by hand injection (a power injector was not available at the time of
the study). This injection speed was adhered to for all patients.
Both contrast agents display comparable relaxivity and distribu-
tion characteristics and therefore would be expected to provide
similar enhancement parameters (Sze et al, 1991). The same
contrast agent was always used for individual patients. Injection
commenced after the first four measurements to allow magnetisa-
tion to reach a steady state. At the end of the dynamic run, the
sequence was repeated with the inversion pulse switched off to
acquire the S0 image. For subsequent scans, patient positioning
and slice orientation was replicated using the previous image set.
Signal intensities were taken from regions of interest drawn
around the tumour and a major blood vessel (e.g. aorta) separately
using an image analysis package, Analyzet (Mayo Clinic,
Rochester, MN, USA). For the tumour, the ROI was drawn based
on the precontrast images after review of the contrast-enhanced
images so that large blood vessels and non-tumour tissues were
avoided. For the major blood vessel, the ROI was drawn based on
the peak arterial enhancement phase of imaging. The positions of
the ROIs were corrected on a time point by time point basis for any
movement during the dynamic run. The shapes of the ROIs were
not changed throughout the dynamic run. The maximum diameter
and appearance on T1- and T2-weighted images of the target lesion
was recorded. The slice position for the dynamic run was checked
on both T1- and T2-weighted images to ensure consistency between
scans and care was taken to ensure that the ROIs had the same
anatomical positions and sizes for both scans.
In clinical DCE–MRI, measurement of S0 at every time point
would result in unacceptably low temporal resolution. Therefore,
we performed a single measurement of S0 at the end of the
dynamic run, by acquiring an image without the inversion
preparation pulse. Equation (1) shows that measured S0 depends
on R1 as there is still some T1 weighting, owing to spin relaxation
during the TR intervals, even when TI-N (the equivalent of
turning the inversion pulse off). A single reading of S0 therefore
produces inaccurate estimates of R1 when R1 differs from its value
at the time when S0 is measured. An estimate of the maximum
error introduced by the assumption of a constant S0 was made
using estimates of R1 precontrast and at maximum enhancement.
Equation (1) was used to predict the true S0 at each of these time
points. R1 calculations were then performed using equation (2),
firstly with the single measured S0 value and second using the true
S0 values (corrected for R1). This error analysis was performed for
typical enhancement curves seen in the clinical study.
The signal intensities were preprocessed in three forms as
summarised in Table 1. First, the raw signal intensities were used
unchanged. In this form, any variability caused by different coil
sensitivity or receiver gain on the two visits, or by different
contrast bolus characteristics remained uncorrected. Secondly, the
signal intensities were divided by the initial area under the arterial
enhancement curve (IAUC-A) for a defined period of time. The
IAUC-A was calculated by first subtracting the average pre-
contrast signal intensities in the artery from the arterial time
series, then using the trapezium rule to calculate the total area
under the resulting change in enhancement out to times of 60 and
180s (IAUC-A(60) and IAUC-A(180)) after contrast injection.
Thirdly, the signal intensities were converted to R1 values using
equation 2) and the S0 image collected after the end of the dynamic
run.
These three data sets were then used to calculate peak
enhancement and the initial area under the enhancement curve
(calculated as above) for 60 and 180s (IAUC(60) and IAUC(180)).
The bidirectional transfer constant K
trans was also calculated using
a two compartment model (Tofts et al, 1999). As the imaging
parameters are optimised for tumour rather than arterial
enhancement, it was not possible to calculate R1 accurately for
the arterial ROI. K
trans was therefore measured in two ways: first
using the raw signal intensities from the tumour and arterial ROIs,
and secondly using the R1 values from the tumour, and a standard
data set for aortic input, similar to previous published data
(Figure 1) (Tofts and Kermode, 1991; Fritz–Hansen et al, 1996).
The timing of the start of this standard arterial input function
(AIF) was measured from the artery imaged in the study.
The data obtained in a previous published clinical trial that
successfully used this technique as a biomarker (Thomas et al,
2005) were re-evaluated. Dynamic contrast-enhanced MR imaging
was performed pre-treatment, on day 2, and at the end of the 28-
day cycle to show changes in the contrast enhancement parameters
of tumours in 35 patients with advanced cancer. K
trans, IAUC(60)
and IAUC(180) were calculated. These data are presented as per
cent change from the pretreatment value after treatment and are
then compared with pharmacokinetic end points.
Statistical analysis
Dynamic contrast-enhanced MR imaging is applied to assess
changes caused by treatment, with patients acting as their own
controls. Previous experience shows a wide interpatient coefficient
of variation (CoV) of 61% in pretreatment values for Ki (Morgan
et al, 2003), equivalent to K
trans (Tofts et al, 1999). This
considerable variability in the pre-treatment enhancement of
tumours makes the percentage rather than absolute changes of
enhancement parameters more amenable to analysis. Statistical
analysis was therefore performed on the percentage changes of the
observed parameter between the two scans. The percentage change
data were tested for normality of distribution by the Shapiro–Wilk
Table 1 Summary of parameters derived from two DCE–MRI scans,
performed 1 week apart, without therapeutic intervention
Parameter
Mean change
(%) CoV (%)
Repeatability
(%)
Unscaled signal
intensity data
PE 21.2 48.6 99.5
IAUC(60) 15.4 50.1 98.0
IAUC(180) 17.0 50.0 98.7
Signal intensity
related to measured
arterial input
function
PE/IAUC-A(180) 12.0 35.7 70.4
IAUC(60)/
IAUC-A(60)
6.6 37.2 70.3
IAUC(180)/
IAUC-A(180)
8.3 37.8 72.1
K
trans 4.6 34 75.0
R1 data
PE 1.0 15.9 29.5
IAUC(60) 1.7 15.8 29.5
IAUC(180) 0.9 16.1 29.9
K
trans 3.1 19.1 36.1
PE¼peak enhancement; IAUC(t)¼initial area under the tumour contrast enhance-
ment curve for first t seconds; IAUC-A(t)¼Initial area under the arterial contrast
enhancement curve for first t seconds.
Method for monitoring tumour treatment using DCE-MRI
B Morgan et al
1422
British Journal of Cancer (2006) 94(10), 1420–1427 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
stest. The mean change and CoV were calculated and expressed as
percentages (Bland and Altman, 1996a). Assuming that the post-
treatment variability is similar, the CoV can be used to assess the
statistical power of studies, or anticipate the patient numbers
required for a study to demonstrate a given degree of treatment
effect. The repeatability value was also evaluated (Bland and
Altman, 1996a), which is defined as the range within which 95% of
measurements will fall, assuming no treatment effect, and is
therefore helpful in assessing the significance of individual patient
results.
RESULTS
Pulse sequence, quantification of R1 and phantom study
Figure 2 shows simulated signal intensities for the IR snapshot
FLASH sequence, using equation (1) and the simplified equation
(2) for the sequence described above. Although there is consider-
able difference between the signal intensities predicted by the two
expressions, Figure 3 shows that R1 can be estimated accurately for
R1 values between 1 and 5s
 1 using either equations (1) and (2).
The marked error occurring at R1 values above 5s
 1 is due to
almost complete relaxation during the TI interval when S
approaches S0, as shown in Figure 2. Thus, with this sequence,
selection of sequence parameters to accurately measure relatively
short R1 compromises the ability to measure long R1 values
accurately. The chosen TIeff is therefore a compromise based on
the pre-contrast and range of R1 seen in tumours during DCE–
MRI.
Clinical study
Of the 11 patients recruited, one patient was excluded owing to
incorrect positioning of the imaging slice on the second scan.
Despite breathing motion, it was possible to maintain the size and
shape of the tumour and arterial ROI in all remaining cases.
Figure 4 demonstrates an example of the images obtained for a
liver metastasis. Although all slices included a major artery (aorta
or iliac artery), ghosting from motion artefact in the phase-
encoded direction was not a significant problem, presumably due
to rapid image acquisition and the nonselective inversion pulse.
The minimum observed precontrast R1, averaged over the whole
0 
2 
4 
6 
8
10
12
14
0 50 100 150 200 250 300
Time (s)
R
1
 
(
s
–
1
)
Figure 1 Change in R1 against time used to represent a standard AIF for
a 0.1mmolkg
 1 gadolinium chelate injected as a bolus. The continuous line
represents the AIF calculated using a formula from a model (Tofts and
Kermode, 1991). The dotted line is our standard AIF created from locally
acquired data, and modified based on published data (Fritz-Hansen et al,
1996) for high concentrations obtained in the early part of the
enhancement curve owing to the contrast bolus.
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Figure 2 Signal intensities for the IR snapshot FLASH sequence
predicted using equation (1) and the simplified equation (2). TR¼3.3ms,
TE¼1.4ms, a¼81,T I¼655ms, TR0¼3000ms.
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Figure 3 Comparison of R1 estimated from the DCE–MRI sequence
using equations (1) and (2) and the ‘true’ value measured by IR-prepared
turbo spin echo sequence in a phantom with R1¼0.5–10s
 1 (A) and
0.5–2s
 1 (B).
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sROI, was 0.95s
 1 (T1¼1.05s). The maximum R1 was 3.4s
 1
(T1¼0.3s).
From Figure 5, it can be seen that the smoothness of the curves
improves with increasing tumour size. As S0 is not continuously
measured as R1 changes, errors are introduced in the dynamic
measurement of R1, which can be estimated as described earlier.
For lesion A (precontrast R1¼1s
 1, maximum R1¼3.4s
 1, and R1
at S0 signal acquisition¼3s
 1), the error in the maximum change
of estimated R1 (2.4s
 1) is 0.13s
 1 or 5.4%. For lesion B, there is
gradually increasing enhancement throughout (precontrast
R1¼1s
 1, maximum R1B2s
 1) and the error in the maximum
change of estimated R1 (1s
 1) is approximately 0.009s
 1, or less
than 1%. For lesions C and D, the maximum estimated error is also
less than 1%. As tissue contrast enhancement changes slowly at the
end of the dynamic sequence (Figure 5), and the S0 sequence is
only mildly sensitive to these changes, the signal intensity in S0
image will change very little in the period from the end of the
dynamic image sequence to the acquisition of the S0 image.
In this study, there was correlation between the difference in the
enhancement parameters of repeated measurements in a single
patient and their mean value for that patient (for K
trans r¼0.42,
Pearson’s correlation coefficient). This causes a skew of the
‘normal’ distribution and a transformation of the data should be
performed in these circumstances (Bland and Altman, 1996b,c).
As stated in the Materials and Methods section, the data were
transformed to percentage difference from the first scan to the
second. There was no significant correlation between the
percentage difference and the mean measured parameters and
therefore no further data transformation was required. For all
listed parameters expressed as percentage change, there was no
significant evidence against a normal distribution (Shapiro–Wilk
test). The mean difference, CoV and repeatability are shown for all
measured parameters in Table 1.
In this study, use of raw signal intensities for calculating peak
enhancement and IAUC resulted in high CoV, which is improved
by dividing by the arterial IAUC. Even though the peak
enhancement is taken from just a single data value along the
enhancement curves, rather than an integration of many more data
points as is the case with IAUC, the reproducibility is very similar
to IAUC. This is a reflection of the smoothness of the tumour
enhancement curves. The K
trans calculated from tumour and
arterial signal intensities showed a higher CoV (34%) than the
K
trans from tumour R1 and a standard AIF (19.1%). This is
probably a reflection of the fact that any real variation in the AIF
between the two scans is outweighed by the fact that the AIF is
measured inaccurately with this sequence.
The individual patient data for two commonly used parameters,
K
trans and IAUC[60], calculated from R1 values, are given in
Table 2. Although no correlation was seen between T2 signal
intensity and enhancement parameters, the second case in Table 2
had very high T2 compared with the other cases, consistent with a
cystic nature of the metastasis. Guidelines from a recent US
national cancer institute workshop on DCE–MRI state that
tumours in a fixed superficial location should be at least 2cm in
diameter and other tumours should be at 3cm in diameter (2004).
This study shows a tendency for greater variability with reducing
ABC
F E D
Figure 4 Image set showing a T1 (A) and T2 (B)-weighted image, demonstrating the tumour and the planned dynamic slice position (white line). Image
(C) is the post contrast S0 image. The dynamic contrast enhancement series is represented by a precontrast (D), and early and late contrast enhanced
images (E and F). The inset image in (D) shows how the ROI is drawn for analysis.
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Figure 5 The R1 time courses for four DCE–MRI series, covering the
range of contrast enhancement and tumour size. The highest variation in R1
between data points is seen for tumour A, which is the smallest measured
tumour. Although the smoothness of the enhancement curve is related to
tumour size, all cases are amenable to analysis.
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ssize, and excluding lesions less that 3cm in diameter reduced CoV.
The colorectal liver metastases group also had lower CoV and
repeatability values (K
trans 14.2 and 26.5% and IAUC(60) 11 and
21.3%, respectively), although this may be related to the fact that
this group had relatively larger tumours.
Review of our previous study using DCE–MRI as a biomarker
for the effect of antiangiogenesis therapy in advanced cancer
(Thomas et al, 2005) showed that for 43 recruited patients with
advanced cancer, in four out of 39 available patients the DCE–MRI
was unsuccessful. In three cases, the ROI could not be accurately
followed through the image series (all these tumours were 3cm or
smaller) and in the other case the imaging slice was planned using
a breath hold image rather than during gentle respiration, causing
misregistration of a 3.1-cm tumour. For the analysed cases, the
difference in K
trans correlated with the pretreatment K
trans value,
but, similar to this study, there was no correlation of the
percentage difference to the pre-treatment K
trans value. There
was good correlation between percent changes on treatment seen
in IAUC and K
trans (Figure 6) calculated from R1 values. After 1 day
(3 doses) of treatment with PTK/ZK, there were similar significant
reductions in K
trans of 4676.3% (mean7s.e. of the mean (s.e.m.))
and IAUC(60) of 43.576.5%. For colorectal liver metastases
receiving 1000mg or more of PTK/ZK per day (n¼14), the effect
was increased with a reduction in K
trans of 55.875.6% and
IAUC(60) of 55.174.9%, again both showing a similar treatment
effect.
DISCUSSION
Dynamic contrast-enhanced MR imaging using an inversion
recovery snapshot FLASH sequence with a relatively long TIeff of
815ms and an interval of 3s between subsequent images,
performed in a coronal oblique plane provides a rapid, reasonably
accurate measure of R1 for values between 1 and 5s
 1, and
therefore of Gd-DTPA concentration during contrast enhance-
ment. The R1 values seen in the clinical arm of this study were
within this range. As S0 is not continuously measured as R1
changes, there are errors of up to 6% in the estimated R1.
Systematic errors also occur in estimating dynamic parameters
based on signal intensity, as MRI signal intensity is not
proportional to Gd-DTPA concentration. These errors do not
necessarily affect the reproducibility of contrast enhancement
parameters but may affect the assessment of change in enhance-
ment owing to treatment.
Using a long TIeff is helpful as it provides good contrast to noise
for low levels of enhancement such as those that may occur in
necrotic tumours. However, this has the disadvantage that arterial
contrast concentration cannot be accurately measured owing to
rapid relaxation during the long TIeff period. Sequences designed
to measure blood concentration of contrast agent (Fritz-Hansen
et al, 1998) have a very short TIeff (150ms), which may show little
or no enhancement in necrotic tumours as they often have a
relatively short precontrast R1.
Measurement of arterial Gd-DTPA concentration (AIF) is
considered important when assessing absolute values of tumour
Table 2 Individual patient data showing tumour size, mean difference, coefficient of variation (CoV) and repeatability for K
trans and IAUC(60) for two
scans, 1 week apart, without therapeutic intervention
K
trans (min
 1) IAUC(60)
Site Primary Size (cm) Scan 1 Scan 2 % change Scan 1 Scan 2 % change
Liver Colorectal 7 0.116 0.111  4.3 10.1 9.7  3.7
Liver Colorectal 2.8 0.018 0.014  22.2 1.2 1.1  15.2
Liver Colorectal 4.7 0.116 0.100  14.0 9.3 8.2  11.6
Liver Colorectal 6 0.186 0.192 3.2 16.6 15.1  9.1
Liver Colorectal 10.4 0.037 0.044 18.9 3.6 4.2 15.6
Liver Colorectal 17 0.085 0.081  4.7 6.7 6.7  0.5
Liver Lung 4.6 0.039 0.051 30.8 3.5 4.3 24.1
Lung Lung 2.5 0.231 0.298 29.0 17.4 21.0 20.8
Lung Lung 7 0.152 0.171 12.5 12.6 14.5 15.0
Lymph node Melanoma 2.4 0.49 0.40  18.5 35.0 28.7  18.0
K
trans IAUC(60)
All cases Mean change (%) 3.1 1.7
CoV (%) 19.1 15.8
Repeatability (%) 36.1 29.5
Size43cm Mean change (%) 6.1 4.3
CoV (%) 15.5 13.9
Repeatability (%) 30.6 26.5
IUAC¼initial area under the contrast enhancement curve. Parameters were calculated using R1 values and a standardised arterial input function for K
trans.
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Figure 6 A comparison of the percentage change of the DCE–MRI
parameters IAUC and K
trans after treatment with PTK/ZK, as calculated
from R1 values.
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smicrocirculation (Evelhoch, 1999). However, the AIF may not be
so important for measuring a treatment effect in patients, unless
there is a change in cardiac function or haemodynamics on
therapy. Techniques that allow accurate, reproducible measure-
ment of the AIF as well as tissue enhancement may well improve
the reproducibility of these parameters, but this study shows that
suboptimal measurement of AIF makes the reproducibility of the
study worse than if a standardised AIF is used.
The simplified equation (equation (2)) used to convert signal
intensities into R1 values does not take into account the signal
saturation due to successive inversion pulses. If the TR0 were to be
shortened, the estimated R1 would become progressively more
inaccurate. Imaging of tumours with a short precontrast R1 can be
a problem with this sequence as in some cases enhancement may
be negative in the first few images of the dynamic series. In a
DCE–MRI study, rectified signal can be recognised if the signal
reduces in the first few images of contrast enhancement. In
practice, this is rarely a problem in liver metastases and this
correction was not required in the clinical arm of this study as
precontrast R1 was always greater than 0.53s
 1. This problem
could be overcome by using saturation recovery rather than
inversion recovery, at the expense of lower contrast at shorter R1
values.
Although respiratory motion causes the tumour to move
throughout the series of image acquisitions, the use of the coronal
oblique plane minimises through plane motion and repositioning
the ROI for each image accounts for in-plane motion. The fact that
there was no need to change the size or shape of the ROI suggests
that the effect of through plane motion was indeed small. The use
of a single region of interest for the whole tumour does not allow
discrimination of regions within the tumour, but it does give a
good signal-to-noise ratio by averaging the signal from a large
volume of tissue and minimises partial volume effects. Acquiring
multiple slices, or three-dimensional images, through the tumour
and then averaging the tumour ROI for each slice would allow even
better signal-to-noise but this would reduce the temporal
resolution of the sequence.
The CoV of the repeated measures depends on the preprocessing
(use of raw signal intensities or conversion to R1), analysis method
(peak enhancement, IAUC or K
trans) and patient cohort used. Peak
enhancement is a simple measure, shown to have similar
reproducibility to IAUC. However, peak enhancement is much
more a reflection of the extravascular, extracellular space volume
fraction (ve) rather than K
trans, as changes in K
trans shift the
position of the peak of the enhancement curve more than its
amplitude, while peak enhancement is, in the limit of large K
trans,
proportional to ve. The validity of using peak enhancement as a
biomarker for angiogenesis would therefore seem questionable.
The study shows it is important to use some method for
‘standardising’ the signal intensities from the dynamic image
series. The results using calculated R1 values for IAUC(60) and
IAUC(180) and R1 values with a standard AIF for K
trans, show a
CoV ranging from 11 to 19.1%. Assuming the post-treatment CoV
is similar, this value can be used to assess the statistical power of
studies or anticipate the patient numbers required for a study.
Interestingly, our previous published data (Morgan et al, 2003)
show a 58% mean reduction of Ki (equivalent to K
trans) with an
s.e.m. of 5.2% for 15 patients with colorectal liver metastases
treated with PTK/ZK with 1000mg or more. This is consistent with
a CoV of 20% (the CoV is equivalent to the standard deviation
(s.d.) of percent changes and the s.e.m. is the s.d. divided by square
root of the number of cases). Reanalysis of our other published
work (Thomas et al, 2005) for patients with liver metastases treated
with PTK/ZK with 1000mg or more (n¼14) showed a 56% mean
reduction in K
trans and a CoV of 21.1%. A CoV of B20%, for both
the reproducibility study and treatment effect, implies a cohort of
10 patients would be expected to show a 25% treatment effect with
statistical significance (power 0.8). If the CoV is reduced to 14%, as
for IAUC(60) in tumours greater than 3cm diameter, then an 18%
treatment effect would show significance. Conversely, if a 40%
treatment effect is expected then only 3–4 patients would be
required to expect a statistically significant result to Po0.05.
Evelhoch et al (2004) measured the median IAUC parameter
(similar to our IAUC(60)) in 19 human tumours with a 7.2-s image
acquisition time. They demonstrated pretreatment tumour inter-
patient CoV of 64% and intrapatient CoV, in repeated measure-
ments without treatment, of 18%, similar to this study. The high
CoV for interpatient tumour measurement supports the notion of
assessing percentage rather than absolute changes. Galbraith et al
(2002) assessed reproducibility in 16 patients with tumours 3cm in
diameter or greater. They use an 11s image acquisition time. Their
data are presented in a slightly different manner and uses both
pixel-by-pixel and ROI analysis. For ROI analysis, the data can be
summarised to show that for a cohort of 16 patients, IAUC can
measure greater than 12% changes and K
trans can measure 14–17%
changes. Similarly, our data extrapolated for 16 patients and
tumours 3cm or greater, (IAUC(60) CoV¼14% and K
trans
CoV¼16%) would be sensitive to 14 and 16% changes,
respectively. Both studies use similar methodology and do not
measure AIF, but our study has an image acquisition time of less
than 500ms as opposed to 7.2 and 11s, dropping the requirement
for multiple breath holds and increasing temporal resolution, but
at the expense of signal to noise of any given image.
The repeatability varied from 26.5% for IAUC(60) (tumours of
diameter greater than 3cm) to 36.1% for K
trans (whole group). This
is a measure of the significance of an individual result. From our
previously published data (Morgan et al, 2003; Thomas et al,
2005), a 40% change in enhancement parameters is considered to
be clinically significant (the change required to predict a tumour
response in colorectal liver metastases). A 40% change in an
individual patient can therefore be considered both a statistically
and a clinically significant finding. Both K
trans and IAUC are shown
to give similar results in the clinical application of this technique
and the improved reproducibility of IAUC in this study suggests it
is a valuable, straightforward method of evaluating contrast
dynamics from DCE–MRI.
In this study, DCE–MRI failed in one patient owing to incorrect
positioning of the slice. The incorrect placement was demonstrated
by studying the reference slice on both T1- and T2-weighted images
but was more apparent on T2-weighted imaging as central tumour
necrosis could be seen. When selecting the target lesion, we suggest
avoiding metastases with very high T2-weighted signal intensity to
avoid purely necrotic/cystic tumours and to select metastatic
deposits with a diameter of greater than 3cm.
In summary, this technique provides a rapid, straightforward,
robust method of measuring tumour enhancement to monitor
therapy. All stages of analysis are simple to perform if equation (2)
is used to calculate R1 and IAUC is used to assess tumour
enhancement. The speed of image acquisition freezes motion,
allowing a wide variety of tumour applications. Also, as multiple
breath holds are not required, the scanning protocol is easier both
for patients and scanning technicians.
REFERENCES
Anonymous (2004) DCE-MRI group consensus recommendations, NCI CIP
MR Workshop on Translational Research in Cancer – Tumor Response.
http://imaging.cancer.gov/reportsandpublications/ReportsandPresentations/
MagneticResonance
Method for monitoring tumour treatment using DCE-MRI
B Morgan et al
1426
British Journal of Cancer (2006) 94(10), 1420–1427 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sBland JM, Altman DG (1996a) Statistics notes: measurement error
proportional to the mean 313, 106. Br Med J 313: 744
Bland JM, Altman DG (1996c) Transforming data. BMJ 312: 770
Bland JM, Altman DG (1996b) Statistics notes: Measurement error
proportional to the mean. 23. Br Med J 313: 106
Buckley DL, Parker GJM (2005) Measuring contrast agent concentration in
T1 weighted dynamic contrast-enhanced MRI. In Dynamic Contrast-
Enhanced Magnetic Resonance Imaging in Oncology, Jackson A, Buckley
DL, Parker GJM (eds), pp 69–79. New York: Springer
Degani H, Gusis V, Weinstein D, Fields S, Strano S (1997) Mapping
pathophysiological features of breast tumors by MRI at high spatial
resolution. Nat Med 3: 780–782
Evelhoch JL (1999) Key factors in the acquisition of contrast kinetic data
for oncology. J Magn Reson Imaging 10: 254–259
Evelhoch JL, LoRusso PM, He ZQ, DelProposto Z, Polin L, Corbett TH,
Langmuir P, Wheeler C, Stone A, Leadbetter J, Ryan AJ, Blakey DC,
Waterton JC (2004) Magnetic resonance imaging measurements of the
response of murine and human tumors to the vascular-targeting agent
ZD6126. Clin Cancer Res 10: 3650–3657
Fritz-Hansen T, Rostrup E, Larsson HBW, Sondergaard L, Ring P,
Henriksen O (1996) Measurement of the arterial concentration of Gd-
DTPA using MRI: a step toward quantitative perfusion imaging. Magn
Reson Med 36: 225–231
Fritz-Hansen T, Rostrup E, Ring PB, Larsson HBW (1998) Quantification of
gadolinium-DTPA concentrations for different inversion times using an
IR-turbo flash pulse sequence: a study on optimizing multislice perfusion
imaging. Magn Reson Imaging 16: 893–899
Galbraith SM, Lodge MA, Taylor NJ, Rustin GJS, Bentzen S, Stirling JJ,
Padhani AR (2002) Reproducibility of dynamic contrast-enhanced MRI
in human muscle and tumours: comparison of quantitative and semi-
quantitative analysis. NMR Biomed 15: 132–142
Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ,
Stirling JJ, Sena L, Padhani AR, Rustin GJS (2003) Combretastatin A4
phosphate has tumor antivascular activity in rat and man as
demonstrated by dynamic magnetic resonance imaging. J Clin Oncol
21: 2831–2842
Haase A (1990) Snapshot flash MRI – applications to T1, T2, and chemical-
shift imaging. Magn Reson Med 13: 77–89
Jayson GC, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, Broughton
L, Wagstaff J, Hakannson L, Groenewegen G, Bailey J, Smith N, Hastings
D, Lawrance J, Haroon H, Ward T, Mcgown AT, Tang M, Levitt D,
Marreaud S, Lehmann FF, Herold M, Zwierzina H (2002) Molecular
imaging and biological evaluation of HuMV833 anti-VEGF antibody:
implications for trial design of antiangiogenic antibodies. J Natl Cancer
Inst 94: 1484–1493
Jivan A, Horsfield MA, Moody AR, Cherryman GR (1997) Dynamic T-1
measurement using snapshot-FLASH MRI. J Magn Res 127: 65–72
Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J,
Magener A, Brix G, Delorme S, Zuna I, van Kaick G (1999)
Pathophysiologic basis of contrast enhancement in breast tumors. J
Magn Reson Imaging 10: 260–266
Leach MO, Brindle KM, Evelhoch JL, Griffiths JR, Horsman MR, Jackson A,
Jayson GC, Judson IR, Knopp MV, Maxwell RJ, McIntyre D, Padhani AR,
Price P, Rathbone R, Rustin GJ, Tofts PS, Tozer GM, Vennart W,
Waterton JC, Williams SR, Workmanw P (2005) The assessment of
antiangiogenic and antivascular therapies in early-stage clinical trials
using magnetic resonance imaging: issues and recommendations. Br J
Cancer 92: 1599–1610
Mayr NA, Hawighorst H, Yuh WTC, Essig M, Magnotta VA, Knopp MV
(1999) MR microcirculation assessment in cervical cancer: Correlations
with histomorphological tumor markers and clinical outcome. J Magn
Reson Imaging 10: 267–276
Morgan B, Horsfield MA, Steward WP (2004) The role of imaging in the
clinical development of antiangiogenic agents. Hematol-Oncol Clin North
Am 18: 1183–1206
Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M, Jivan A, Horsfield
MA, Mross K, Ball HA, Lee L, Mietlowski W, Fuxius S, Unger C, O’Byrne
K, Henry A, Cherryman GR, Laurent D, Dugan M, Marme D, Steward WP
(2003) Dynamic contrast-enhanced magnetic resonance imaging as a
biomarker for the pharmacological response of PTK787/ZK 222584, an
inhibitor of the vascular endothelial growth factor receptor tyrosine
kinases, in patients with advanced colorectal cancer and liver metastases:
results from two phase I studies. JClin Oncol 21: 3955–3964
Parker GJM, Buckley DL (2005) Tracer kinetic modelling for T1 weighted
DCE-MRI. In Dynamic Contrast-Enhanced Magnetic Resonance Imaging
in Oncology, Jackson A, Buckley DL, Parker GJM (eds), pp 81–92. New
York: Springer
Parker GJM, Suckling J, Tanner SF, Padhani AR, Revell PB, Husband JE,
Leach MO (1997) Probing tumor microvascularity by measurement,
analysis and display of contrast agent uptake kinetics. J Magn Reson
Imaging 7: 564–574
Reddick WE, Taylor JS, Fletcher BD (1999) Dynamic MR imaging
(DEMRI) of microcirculation in bone sarcoma. J Magn Reson Imaging
10: 277–285
Rehman S, Jayson GC (2005) Molecular imaging of antiangiogenic agents.
Oncologist 10: 92–103
Sze G, Brant-Zawadzki M, Haughton VM, Maravilla KR, McNamara MT,
Kumar AJ, Aisen AM, Dreisbach JN, Bradley Jr WG, Weinreb JC (1991)
Multicenter study of gadodiamide injection as a contrast agent in MR
imaging of the brain and spine. Radiology 181: 693–699
Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, Reddick WE, Runge
VM, Mayr N (1999) MR imaging of tumor microcirculation: promise for
the new millenium. J Magn Reson Imaging 10: 903–907
Thomas AL, Morgan B, Horsfield MA, Higginson A, Kay A, Lee L, Masson
E, Puccio-Pick M, Laurent D, Steward WP (2005) Phase I study of the
safety, tolerability, pharmacokinetics, and pharmacodynamics of
PTK787/ZK 222584 administered twice daily in patients with advanced
cancer. J Clin Oncol 23: 4162–4171
Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp M, Larsson
HBW, Lee TY, Mayr NA, Parker GJM, Port RE, Taylor J, Weisskoff RM
(1999) Estimating kinetic parameters from dynamic contrast-enhanced
T- 1-weighted MRI of a diffusable tracer: standardized quantities and
symbols. J Magn Reson Imaging 10: 223–232
Tofts PS, Kermode AG (1991) Measurement of the blood—brain barrier
permeability and leakage space using dynamic Mr imaging. 1.
Fundamental-concepts. Magn Reson Med 17: 357–367
Yuh WTC (1999) An exciting and challenging role for the advanced
contrast MR imaging. J Magn Reson Imaging 10: 221–222
Method for monitoring tumour treatment using DCE-MRI
B Morgan et al
1427
British Journal of Cancer (2006) 94(10), 1420–1427 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s